| 摘要: |
| 目的 探讨布地奈德联合肺表面活性物质（PS）防治早产儿支气管肺发育不良（BPD）的临床疗效。方法 选取2016年1月～2018年12月该院出生体重≤1500g或胎龄≤32周、合并呼吸窘迫综合征（RDS）、需要呼吸支持的早产儿123例，随机分为观察组（61例）和对照组（62例），观察组采用布地奈德+PS治疗，对照组采用PS治疗。比较治疗前后两组血气分析、氧合指数（OI）、呼吸机通气时间、吸氧时间变化情况及BPD发生率、其他合并症的发生率情况。结果 给药后2h、48h、第3天、第7天、第2周、第3周、第4周两组pH、PaCO2、PaO2、OI比较，差异均有统计学意义（P＜0.05）：两组在给药后2h、48h pH、PaO2、OI均高于给药前，PaCO2低于给药前；观察组在给药后2h、48h、第7天、第2周、第3周时pH、PaO2、OI均高于对照组，PaCO2低于对照组，第4周PaO2、OI均高于对照组。观察组患儿呼吸机通气时间、吸氧时间均短于对照组，BPD发生率低于对照组，差异均有统计学意义（P＜0.05）；两组其他合并症发生率差异无统计学意义（P＞0.05）。结论 布地奈德+PS较单用PS更能有效改善肺功能、减轻肺炎性损伤，防治BPD，并未增加合并症发生率。 |
| 关键词: 布地奈德 肺表面活性物质 支气管肺发育不良 早产儿 |
| DOI： |
| 分类号: |
| 基金项目: |
|
| Clinical study of budesonide combined with pulmonary surfactant for preventing and treating bronchopulmonary dysplasia in premature infants |
|
CAI Lin
|
|
Shenzhen Nanshan Hospital
|
| Abstract: |
| Objective To explore the clinical efficacy of budesonide combined with pulmonary surfactant for preventing and treating bronchopulmonary dysplasia（BPD） in premature infants. Methods From January 2016 to December 2018, 123 preterm infants with birth weight ≤1500g or gestational age ≤32 weeks, combined with respiratory distress syndrome (RDS) and respiratory support were randomly divided into observation group (61 cases) and control group (62 cases). The observation group was treated with budesonide + PS, while the control group was treated with PS. The changes were compared between the two groups in arterial blood gas indexes, oxygenation index (OI), duration of mechanical ventilation,duration of oxygen supplementation, incidence of BPD, and incidence of other complications before and after treatment. Results At 2h, 48h, 3d, 7d, 2nd, 3rd and 4th week after administration, pH, PaCO2, PaO2 and OI showed statistically significant difference between the two groups（P＜0.05）：the pH, PaO2 and OI of the two groups at 2h and 48h after administration were higher than before administration, and PaCO2 was lower than before administration; at 2h, 48h, 7d, 2nd and 3rd week after administration, the pH, PaO2, OI in the observation group were higher than those in the control group, and PaCO2 was lower than that in the control group;and on the 4th week, PaO2 and OI in the observation group were higher than those in the control group. Compared with the control group, the observation group had shorter duration of mechanical ventilation and duration of oxygen supplementation, lower incidence of BPD; and the difference was statistically significant（P＜0.05）.There was no significant difference in the incidence of other complications between the two groups （P＞0.05）. Conclusion Compared with PS alone, budesonide+PS can effectively improve lung function, alleviate inflammatory injury of the lung, prevent and treat BPD, but does not increase the incidence of complications. |
| Key words: Budesonide Pulmonary surfactant Bronchopulmonary dysplasia Premature infants |
